1736.TW
Johnson Health Tech. Co., Ltd. [1736.TW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1736.TW Stock Summary
Top 10 Correlated Stocks
1736.TW
In the News
1736.TW Financial details
Company Rating
Buy
Market Cap
24.29B
Income
709.64M
Revenue
38.07B
Book val./share
31.83
Cash/share
7.83
Dividend
0.6
Dividend %
0.88%
Employees
1.29K
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
35.17
Forward P/E
-
PEG
1.63
P/S
0.56
P/B
2.19
P/C
9.51
P/FCF
10.33
Quick Ratio
0.66
Current Ratio
1.25
Debt / Equity
1.5
LT Debt / Equity
0.62
-
-
EPS (TTM)
2.34
EPS next Y
-
EPS next Q
-
EPS this Y
216.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-11.29%
Revenue last 5Y
8.45%
Revenue Q/Q
31.48%
EPS Q/Q
77.05%
-
-
-
-
SMA20
6.94%
SMA50
16.67%
SMA100
10%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
6%
ROC
0.09%
Gross Margin
47%
Oper. Margin
4%
Profit Margin
2%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
56.1-83.1
52W High
-10.24%
52W Low
+33.04%
RSI
54
Rel Volume
1.34
Avg Volume
822.24K
Volume
1.1M
Perf Week
-1.72%
Perf Month
4.93%
Perf Quarter
4.2%
Perf Half Y
3.33%
-
-
-
-
Beta
0.394
-
-
Volatility
2.23%, 3.07%
Prev Close
-3.12%
Price
74.5
Change
-4.36%
1736.TW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 83.67 | 93.72 | 101.72 | 111.07 | 125.67 | |
| Net income per share | 4.26 | 2.24 | 0.33 | 0.74 | 2.34 | |
| Operating cash flow per share | 3.11 | 9.72 | -11.69 | 1.3 | 13.42 | |
| Free cash flow per share | 0.77 | 6.94 | -14.2 | -0.16 | 11.08 | |
| Cash per share | 10.84 | 10.93 | 8.67 | 11.7 | 7.83 | |
| Book value per share | 30.11 | 30.88 | 28.02 | 31.31 | 31.83 | |
| Tangible book value per share | 26.06 | 24.54 | 21.73 | 21.89 | 22.54 | |
| Share holders equity per share | 30.11 | 30.88 | 28.02 | 31.31 | 31.83 | |
| Interest debt per share | 34.89 | 39.36 | 54.83 | 63.36 | 49.09 | |
| Market cap | 25.77B | 28.03B | 17.04B | 21.03B | 20.81B | |
| Enterprise value | 32.88B | 36.48B | 30.85B | 36.42B | 34.87B | |
| P/E ratio | 19.94 | 41.26 | 171.44 | 93.5 | 29.32 | |
| Price to sales ratio | 1.02 | 0.99 | 0.55 | 0.63 | 0.55 | |
| POCF ratio | 27.33 | 9.53 | -4.82 | 53.59 | 5.12 | |
| PFCF ratio | 110.67 | 13.33 | -3.96 | -434.56 | 6.2 | |
| P/B Ratio | 2.82 | 3 | 2.01 | 2.22 | 2.16 | |
| PTB ratio | 2.82 | 3 | 2.01 | 2.22 | 2.16 | |
| EV to sales | 1.3 | 1.29 | 1 | 1.08 | 0.92 | |
| Enterprise value over EBITDA | 11.81 | 16.78 | 17.61 | 20.41 | 13.21 | |
| EV to operating cash flow | 34.86 | 12.4 | -8.72 | 92.8 | 8.58 | |
| EV to free cash flow | 141.19 | 17.36 | -7.18 | -752.45 | 10.39 | |
| Earnings yield | 0.05 | 0.02 | 0.01 | 0.01 | 0.03 | |
| Free cash flow yield | 0.01 | 0.07 | -0.25 | 0 | 0.16 | |
| Debt to equity | 1.14 | 1.26 | 1.94 | 2 | 1.5 | |
| Debt to assets | 0.39 | 0.38 | 0.47 | 0.49 | 0.4 | |
| Net debt to EBITDA | 2.55 | 3.89 | 7.89 | 8.62 | 5.33 | |
| Current ratio | 1.4 | 1.24 | 1.11 | 1.07 | 1.3 | |
| Interest coverage | 9.92 | 7.29 | 4.35 | 2.26 | 3.29 | |
| Income quality | 0.58 | 3.02 | -21.61 | 1.29 | 5.73 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Payout ratio | 0.15 | 0.62 | 3.41 | 0.67 | 0.26 | |
| Sales general and administrative to revenue | 0.23 | 0.19 | 0.2 | 0.21 | 0.2 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.05 | 0.09 | 0.08 | 0.07 | 0.08 | |
| Capex to operating cash flow | -0.75 | -0.29 | 0.21 | -1.12 | -0.17 | |
| Capex to revenue | -0.03 | -0.03 | -0.02 | -0.01 | -0.02 | |
| Capex to depreciation | -0.81 | -0.85 | -0.73 | -0.37 | -0.51 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 53.74 | 39.49 | 14.39 | 22.88 | 40.97 | |
| ROIC | 0.07 | 0.04 | 0.02 | 0.01 | 0.03 | |
| Return on tangible assets | 0.05 | 0.02 | 0 | 0.01 | 0.02 | |
| Graham Net | -16.13 | -24.53 | -35.1 | -38.84 | -38.33 | |
| Working capital | 5.21B | 3.8B | 2.39B | 1.62B | 5.49B | |
| Tangible asset value | 7.9B | 7.43B | 6.57B | 6.62B | 6.83B | |
| Net current asset value | 563.32M | -1.33B | -2.42B | -2.96B | -3.16B | |
| Invested capital | 1.14 | 1.26 | 1.94 | 2 | 1.5 | |
| Average receivables | 8.49B | 8.37B | 8.67B | 9.99B | 10.97B | |
| Average payables | 3.41B | 3.83B | 4.25B | 4.23B | 4.19B | |
| Average inventory | 6.03B | 7.25B | 9.81B | 11.74B | 10.42B | |
| Days sales outstanding | 121.78 | 106.36 | 107.52 | 118.52 | 105.7 | |
| Days payables outstanding | 94.92 | 105.44 | 90.39 | 82.4 | 71.74 | |
| Days of inventory on hand | 186.26 | 193.75 | 252.54 | 226.77 | 158.62 | |
| Receivables turnover | 3 | 3.43 | 3.39 | 3.08 | 3.45 | |
| Payables turnover | 3.85 | 3.46 | 4.04 | 4.43 | 5.09 | |
| Inventory turnover | 1.96 | 1.88 | 1.45 | 1.61 | 2.3 | |
| ROE | 0.14 | 0.07 | 0.01 | 0.02 | 0.07 | |
| Capex per share | -2.34 | -2.78 | -2.51 | -1.46 | -2.33 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 37.97 | 23.22 | 28.51 | 31.94 | 42 | |
| Net income per share | 1.76 | -2.14 | 1.1 | 1.22 | 2.16 | |
| Operating cash flow per share | 3.83 | -2.02 | 3.16 | 2.97 | 8.45 | |
| Free cash flow per share | 3.96 | -2.25 | 2.45 | 2.48 | 7.54 | |
| Cash per share | 11.7 | 9.18 | 7.67 | 7.35 | 7.83 | |
| Book value per share | 31.31 | 29.16 | 29.41 | 31.28 | 31.83 | |
| Tangible book value per share | 21.89 | 19.81 | 20.04 | 21.82 | 22.54 | |
| Share holders equity per share | 31.31 | 29.16 | 29.41 | 31.28 | 31.83 | |
| Interest debt per share | 62.79 | 62.41 | 58.78 | 57.08 | 48.09 | |
| Market cap | 21.03B | 20.2B | 21.75B | 23.84B | 20.81B | |
| Enterprise value | 36.42B | 36.22B | 37.14B | 38.82B | 34.87B | |
| P/E ratio | 9.84 | -7.81 | 16.31 | 16.13 | 7.96 | |
| Price to sales ratio | 1.83 | 2.87 | 2.52 | 2.46 | 1.64 | |
| POCF ratio | 18.15 | -33.07 | 22.73 | 26.54 | 8.13 | |
| PFCF ratio | 17.55 | -29.68 | 29.35 | 31.77 | 9.11 | |
| P/B Ratio | 2.22 | 2.29 | 2.44 | 2.52 | 2.16 | |
| PTB ratio | 2.22 | 2.29 | 2.44 | 2.52 | 2.16 | |
| EV to sales | 3.17 | 5.15 | 4.3 | 4.01 | 2.74 | |
| Enterprise value over EBITDA | 32.77 | -141.58 | 39.47 | 35.88 | 21.5 | |
| EV to operating cash flow | 31.42 | -59.29 | 38.81 | 43.2 | 13.63 | |
| EV to free cash flow | 30.38 | -53.2 | 50.12 | 51.73 | 15.26 | |
| Earnings yield | 0.03 | -0.03 | 0.02 | 0.02 | 0.03 | |
| Free cash flow yield | 0.06 | -0.03 | 0.03 | 0.03 | 0.11 | |
| Debt to equity | 2 | 2.13 | 1.99 | 1.81 | 1.5 | |
| Debt to assets | 0.49 | 0.53 | 0.51 | 0.47 | 0.4 | |
| Net debt to EBITDA | 13.85 | -62.6 | 16.36 | 13.84 | 8.67 | |
| Current ratio | 1.07 | 1.47 | 1.47 | 1.25 | 1.3 | |
| Interest coverage | 9.72 | -5.2 | 6.03 | 7.27 | 17.28 | |
| Income quality | 1.59 | 0.85 | 1.98 | 1.6 | 3.91 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0.01 | |
| Payout ratio | 0.28 | 0 | 0 | 0 | 0.28 | |
| Sales general and administrative to revenue | 0.18 | 0.28 | 0.22 | 0.19 | 0.15 | |
| Research and developement to revenue | 0.02 | 0.03 | 0.03 | 0.02 | 0.03 | |
| Intangibles to total assets | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | |
| Capex to operating cash flow | 0.03 | 0.11 | -0.23 | -0.16 | -0.11 | |
| Capex to revenue | 0 | -0.01 | -0.02 | -0.02 | -0.02 | |
| Capex to depreciation | 0.13 | -0.22 | -0.63 | -0.38 | -0.76 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 35.26 | 37.43 | 26.98 | 29.3 | 39.31 | |
| ROIC | 0.02 | -0.02 | 0.01 | 0.02 | 0.03 | |
| Return on tangible assets | 0.01 | -0.02 | 0.01 | 0.01 | 0.02 | |
| Graham Net | -38.84 | -38.32 | -37.12 | -37.69 | -38.33 | |
| Working capital | 1.62B | 7.43B | 7.04B | 4.67B | 5.49B | |
| Tangible asset value | 6.62B | 6B | 6.07B | 6.61B | 6.83B | |
| Net current asset value | -2.96B | -3.56B | -3.59B | -3.25B | -3.16B | |
| Invested capital | 2 | 2.13 | 1.99 | 1.81 | 1.5 | |
| Average receivables | 10.03B | 9.96B | 9.15B | 9.78B | 10.65B | |
| Average payables | 4.59B | 3.66B | 2.91B | 3.59B | 4.23B | |
| Average inventory | 12.4B | 11.57B | 10.84B | 10.66B | 10.02B | |
| Days sales outstanding | 85.49 | 115.3 | 96.76 | 95.49 | 77.99 | |
| Days payables outstanding | 62.71 | 72.56 | 55.33 | 79.49 | 55.14 | |
| Days of inventory on hand | 172.6 | 271.11 | 204.55 | 199.78 | 121.92 | |
| Receivables turnover | 1.05 | 0.78 | 0.93 | 0.94 | 1.15 | |
| Payables turnover | 1.44 | 1.24 | 1.63 | 1.13 | 1.63 | |
| Inventory turnover | 0.52 | 0.33 | 0.44 | 0.45 | 0.74 | |
| ROE | 0.06 | -0.07 | 0.04 | 0.04 | 0.07 | |
| Capex per share | 0.13 | -0.23 | -0.71 | -0.49 | -0.9 |
1736.TW Frequently Asked Questions
What is Johnson Health Tech. Co., Ltd. stock symbol ?
Johnson Health Tech. Co., Ltd. is a TW stock and trading under the symbol 1736.TW
What is Johnson Health Tech. Co., Ltd. stock quote today ?
Johnson Health Tech. Co., Ltd. stock price is $74.5 today.
Is Johnson Health Tech. Co., Ltd. stock public?
Yes, Johnson Health Tech. Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 822.24K
- Market Capitalization 24.29B
- Employee 1.29K
- CEO Mr. Jason Lo
- Headquarters Taichung,TW
- IPO Date 2003-01-09
-
Website
https://www.johnsonfitness.com.tw 
Johnson Health Tech. Co., Ltd. manufactures and sells sports and fitness equipment in the Americas, Europe, China, and internationally. It offers cardiovascular and weight training equipment, and related electronic components, as well as video transmission and streaming service; researches, develops, manufactures, and trades in massage chairs; and sells food products. Johnson Health Tech. Co., Ltd. was incorporated in 1975 and is based in Taichung City, Taiwan.
